Literature DB >> 22033823

A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide.

Omid Motabar1, Ehud Goldin, William Leister, Ke Liu, Noel Southall, Wenwei Huang, Juan J Marugan, Ellen Sidransky, Wei Zheng.   

Abstract

Glucocerebrosidase is a lysosomal enzyme that catalyzes the hydrolysis of glucosylceramide to form ceramide and glucose. A deficiency of lysosomal glucocerebrosidase due to genetic mutations results in Gaucher disease, in which glucosylceramide accumulates in the lysosomes of certain cell types. Although enzyme replacement therapy is currently available for the treatment of type 1 Gaucher disease, the neuronopathic forms of Gaucher disease are still not treatable. Small molecule drugs that can penetrate the blood-brain barrier, such as pharmacological chaperones and enzyme activators, are new therapeutic approaches for Gaucher disease. Enzyme assays for glucocerebrosidase are used to screen compound libraries to identify new lead compounds for drug development for the treatment of Gaucher disease. But the current assays use artificial substrates that are not physiologically relevant. We developed a glucocerebrosidase assay using the natural substrate glucosylceramide coupled to an Amplex-red enzyme reporting system. This assay is in a homogenous assay format and has been miniaturized in a 1,536-well plate format for high throughput screening. The assay sensitivity and robustness is similar to those seen with other glucocerebrosidase fluorescence assays. Therefore, this new glucocerebrosidase assay is an alternative approach for high throughput screening.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22033823      PMCID: PMC3351006          DOI: 10.1007/s00216-011-5496-z

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  23 in total

Review 1.  Therapy for Gaucher disease: don't stop thinking about tomorrow.

Authors:  Ellen Sidransky; Mary E LaMarca; Edward I Ginns
Journal:  Mol Genet Metab       Date:  2006-11-03       Impact factor: 4.797

2.  Differentiation of beta-glucocerebrosidase from beta-glucosidase in human tissues using sodium taurocholate.

Authors:  S P Peters; P Coyle; R H Glew
Journal:  Arch Biochem Biophys       Date:  1976-08       Impact factor: 4.013

3.  Neuropathic Gaucher's disease with normal 4-methylumbelliferyl-beta-glucosidase activity in the liver.

Authors:  M Owada; T Sakiyama; T Kitagawa
Journal:  Pediatr Res       Date:  1977-05       Impact factor: 3.756

4.  A flow cytometric assay for lysosomal glucocerebrosidase.

Authors:  H H van Es; M Veldwijk; M Havenga; D Valerio
Journal:  Anal Biochem       Date:  1997-05-01       Impact factor: 3.365

5.  The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.

Authors:  Richie Khanna; Elfrida R Benjamin; Lee Pellegrino; Adriane Schilling; Brigitte A Rigat; Rebecca Soska; Hadis Nafar; Brian E Ranes; Jessie Feng; Yi Lun; Allan C Powe; David J Palling; Brandon A Wustman; Raphael Schiffmann; Don J Mahuran; David J Lockhart; Kenneth J Valenzano
Journal:  FEBS J       Date:  2010-02-10       Impact factor: 5.542

6.  Screening method for inhibitors against formosan subterranean termite beta-glucosidases in vivo.

Authors:  Betty C R Zhu; Gregg Henderson; Roger A Laine
Journal:  J Econ Entomol       Date:  2005-02       Impact factor: 2.381

7.  Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators.

Authors:  Juan J Marugan; Wei Zheng; Omid Motabar; Noel Southall; Ehud Goldin; Ellen Sidransky; Ronald A Aungst; Ke Liu; Subir Kumar Sadhukhan; Christopher P Austin
Journal:  Eur J Med Chem       Date:  2010-02-01       Impact factor: 6.514

8.  A sensitive and reproducible fluorescent-based HPLC assay to measure the activity of acid as well as neutral beta-glucocerebrosidases.

Authors:  Yasuhiro Hayashi; Kouta Zama; Eriko Abe; Nozomu Okino; Takehiko Inoue; Kousaku Ohno; Makoto Ito
Journal:  Anal Biochem       Date:  2008-07-30       Impact factor: 3.365

9.  High throughput screening for inhibitors of alpha-galactosidase.

Authors:  Omid Motabar; Ke Liu; Noel Southall; Juan J Marugan; Ehud Goldin; Ellen Sidransky; Wei Zheng
Journal:  Curr Chem Genomics       Date:  2010-12-03

Review 10.  Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.

Authors:  Giancarlo Parenti
Journal:  EMBO Mol Med       Date:  2009-08       Impact factor: 12.137

View more
  11 in total

1.  Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations.

Authors:  Mohammad Arif Hossain; Katsumi Higaki; Seiji Saito; Kazuki Ohno; Hitoshi Sakuraba; Eiji Nanba; Yoshiyuki Suzuki; Keiichi Ozono; Norio Sakai
Journal:  J Hum Genet       Date:  2015-06-25       Impact factor: 3.172

2.  A high-throughput sphingomyelinase assay using natural substrate.

Authors:  Miao Xu; Ke Liu; Noel Southall; Juan J Marugan; Alan T Remaley; Wei Zheng
Journal:  Anal Bioanal Chem       Date:  2012-06-19       Impact factor: 4.142

3.  Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity.

Authors:  Thai Leong Yap; Arash Velayati; Ellen Sidransky; Jennifer C Lee
Journal:  Mol Genet Metab       Date:  2012-11-28       Impact factor: 4.797

4.  In situ visualization of glucocerebrosidase in human skin tissue: zymography versus activity-based probe labeling.

Authors:  Jeroen van Smeden; Irini M Dijkhoff; Richard W J Helder; Hanin Al-Khakany; Daphne E C Boer; Anne Schreuder; Wouter W Kallemeijn; Samira Absalah; Herman S Overkleeft; Johannes M F G Aerts; Joke A Bouwstra
Journal:  J Lipid Res       Date:  2017-10-12       Impact factor: 5.922

5.  Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.

Authors:  Anwesha Sanyal; Mark P DeAndrade; Hailey S Novis; Steven Lin; Jianjun Chang; Nathalie Lengacher; Julianna J Tomlinson; Malú G Tansey; Matthew J LaVoie
Journal:  Mov Disord       Date:  2020-02-08       Impact factor: 10.338

6.  Association Between Glucocerebrosidase Mutations and Parkinson's Disease in Ireland.

Authors:  Diana A Olszewska; Allan McCarthy; Alexandra I Soto-Beasley; Ronald L Walton; Brian Magennis; Russell L McLaughlin; Orla Hardiman; Owen A Ross; Tim Lynch
Journal:  Front Neurol       Date:  2020-06-30       Impact factor: 4.003

Review 7.  Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity.

Authors:  Daniel Ysselstein; Tiffany J Young; Maria Nguyen; Shalini Padmanabhan; Warren D Hirst; Nicolas Dzamko; Dimitri Krainc
Journal:  Mov Disord       Date:  2021-10-06       Impact factor: 9.698

8.  A high-throughput screening assay using Krabbe disease patient cells.

Authors:  Jameson Ribbens; Grace Whiteley; Hirokazu Furuya; Noel Southall; Xin Hu; Juan Marugan; Marc Ferrer; Gustavo H B Maegawa
Journal:  Anal Biochem       Date:  2012-11-05       Impact factor: 3.365

9.  Defective Self-Renewal and Differentiation of GBA-Deficient Neural Stem Cells Can Be Restored By Macrophage Colony-Stimulating Factor.

Authors:  Hyun Lee; Jae-sung Bae; Hee Kyung Jin
Journal:  Mol Cells       Date:  2015-08-18       Impact factor: 5.034

10.  Tool compounds robustly increase turnover of an artificial substrate by glucocerebrosidase in human brain lysates.

Authors:  Zdenek Berger; Sarah Perkins; Claude Ambroise; Christine Oborski; Matthew Calabrese; Stephen Noell; David Riddell; Warren D Hirst
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.